Literature DB >> 31309339

Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?

Ramya Janardana1, Aswin M Nair1, Ajit K Surin1, John Anthony Jude Prakash2, Mahasampath Gowri3, Debashish Danda4.   

Abstract

AIM AND METHODS: A single-centre retrospective study was conducted using electronic medical records (EMR) of inpatients and outpatients with the diagnosis of "scleroderma" or "systemic sclerosis" visiting our clinic over the preceding 5 years.
RESULTS: A total of 327 patients' charts met our selection criteria; 301 were females. The median (IQR (inter quartile range)) age at onset of first non-Raynaud's symptom was 34.67 (27-43) years and median (IQR) disease duration prior to presentation to our department was 2.5 (1-5) years. Of these, 310 (94.8%) belonged to diffuse systemic sclerosis variety, 13 (4%) had limited systemic sclerosis, and 4 (1.2%) were of sine scleroderma type. A total of 289/302 (95.7%) patients were positive for ANA; of them, 245/327 (74.9%) were Scl-70 antibody-positive and 4% were CENP antibody-positive. Interstitial lung disease (ILD) was present in 288/327 (88.1%) patients. Among patients with available baseline forced vital capacity (FVC) data, 20% had a normal lung function and 28.4% had severe restriction. Pulmonary hypertension as assessed by echocardiography was present in 8.1% of patients. A significant association of Scl-70 antibody positivity with the presence of interstitial lung disease (ILD) (p = 0.000) and pulmonary hypertension (p = 0.035) was seen. On the other hand, presence of CENP antibody showed a protective trend against muscle weakness and/or muscle enzyme elevation (p = 0.052). Presence of arthritis was protective against development of digital ulceration (p = 0.021) and PAH (0.004). Patients younger than 40 years of age had significantly higher frequency of Scl-70 positivity (p = 0.038), whereas CENP antibody positivity was more likely in those aged > 40 years (p = 0.002).
CONCLUSION: Younger age of onset and high prevalence of Scl-70 antibody are unique South Asian features common with large Indian, Thai, and Chinese series. High prevalence of ILD is a feature common to Indian and Chinese series. Strong correlation of Scl-70 antibody with younger age and pulmonary hypertension were unique features of our cohort. KEY POINTS: • Asian Indian scleroderma patients are younger by 2 decades compared to Caucasian series. • Higher prevalence of Scl-70 antibody, its association with young age, interstitial lung disease and pulmonary hypertension are features of our cohort. • High prevalence of interstitial lung disease (88.1%) was noted ; among those with baseline spirometry data (141/327), two thirds(66%) had moderate to severe restriction. • Younger age at onset, higher prevalence of Scl-70 antibody are features common to other Indian, Thai and Chinese series.

Entities:  

Keywords:  Anti-Scl-70 antibody; Interstitial lung disease; Pulmonary arterial hypertension; Scleroderma; Younger

Year:  2019        PMID: 31309339     DOI: 10.1007/s10067-019-04659-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

Review 1.  Assessment of disease severity and prognosis.

Authors:  T A Medsger; S Bombardieri; L Czirjak; R Scorza; A Della Rossa; W Bencivelli
Journal:  Clin Exp Rheumatol       Date:  2003       Impact factor: 4.473

2.  Progressive systemic sclerosis in south India.

Authors:  V Krishnamurthy; R Porkodi; S Ramakrishnan; C P Rajendran; R Madhavan; K Achuthan; M Parthiban; A N Chandrasekaran
Journal:  J Assoc Physicians India       Date:  1991-03

3.  Profile of systemic sclerosis in a tertiary care center in North India.

Authors:  Vinod K Sharma; Tejasvi Trilokraj; Binod K Khaitan; Sumanth M Krishna
Journal:  Indian J Dermatol Venereol Leprol       Date:  2006 Nov-Dec       Impact factor: 2.545

4.  Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.

Authors:  Chingching Foocharoen; Prangsuporn Suwannachat; Sittichai Netwijitpan; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Ratanavadee Nanagara
Journal:  Int J Rheum Dis       Date:  2014-10-08       Impact factor: 2.454

5.  [The prevalence and clinical significance of arthritis in patients with systemic sclerosis].

Authors:  Chanyuan Wu; Qian Wang; Dong Xu; Mengtao Li; Yong Hou; Xiaofeng Zeng
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2014-06

6.  Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography.

Authors:  H Schurawitzki; R Stiglbauer; W Graninger; C Herold; D Pölzleitner; O C Burghuber; D Tscholakoff
Journal:  Radiology       Date:  1990-09       Impact factor: 11.105

7.  Clinical features of 405 Japanese patients with systemic sclerosis.

Authors:  Atsushi Hashimoto; Hirahito Endo; Hirobumi Kondo; Shunsei Hirohata
Journal:  Mod Rheumatol       Date:  2011-08-28       Impact factor: 3.023

8.  Epidemiological study of patients with systemic sclerosis in Tokyo.

Authors:  T Tamaki; S Mori; K Takehara
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

9.  Severe restrictive lung disease in systemic sclerosis.

Authors:  V D Steen; C Conte; G R Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1994-09

10.  Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Authors:  Florian M P Meier; Klaus W Frommer; Robert Dinser; Ulrich A Walker; Laszlo Czirjak; Christopher P Denton; Yannick Allanore; Oliver Distler; Gabriela Riemekasten; Gabriele Valentini; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

View more
  3 in total

Review 1.  Systemic sclerosis in Asians: Are there racial differences?

Authors:  Sue-Ann Ng; Andrea Hsiu Ling Low
Journal:  J Scleroderma Relat Disord       Date:  2022-02-03

2.  Mycophenolate in scleroderma-associated interstitial lung disease: Real-world data from rheumatology and pulmonology clinics in South Asia.

Authors:  Ramya Janardana; Aparna Irodi; Pramod P Chebbi; Ruchika Goel; Leena R Vimala; Shivraj Padiyar; Anoof Peediyakal; John Mathew; Aswin Nair; Devasahayam J Christopher; Debashish Danda
Journal:  J Scleroderma Relat Disord       Date:  2021-06-30

Review 3.  Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment.

Authors:  Shirin Assar; Hosna Khazaei; Maryam Naseri; Fardous El-Senduny; Saeideh Momtaz; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  J Immunol Res       Date:  2021-06-24       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.